| Subject: | Updated Prescribing Information for Desmopressin Acetate |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Wed, 5 Dec 2007 - 10:00 am |
| Audience: Endocrinologists, pediatricians, other healthcare professionalsThe FDA has notified healthcare professionals and patients of the Agency's request that manufacturers update the prescribing information for Desmopressin Acetate (marketed as DDAVP Nasal Spray, DDAVP Rhinal Tube, DDAVP, DDVP, Minirin, and Stimate Nasal Spray) to include important new safety information about severe hyponatremia and seizures. Certain patients, including children treated with the intranasal formulation... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
Customizable Documents and Tools:
External Links:
|
|
StayAlert!® Virtual Compliance Administrator™ keeps clients informed by email of any changes to Federal regulations, including Joint Commission (TJC, formerly JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG, and many more, and also provides downloadable tools to ensure compliance. StayAlert! is a premium product sold as an annual site-license subscription. With the site license, the client can sign up an unlimited number of users for the email alerts and access to the StayAlert! online regulatory library. The strength of StayAlert! rests in its ability to allow healthcare organizations to streamline their businesses using the Internet as a foundation architecture. StayAlert! provides cost containment and reduction through elimination of unnecessary overhead, and work caused by errors or poor access to information. |
|
